temozolomide

[Cell Death & Disease] Researchers showed that P2X7A and B receptor isoform levels were inversely modulated during the post-irradiation recovery phase in glioblastoma cells.

[Clinical Cancer Research] Researchers assessed regulatory T cells and cytotoxic T lymphocytes in the tumor microenvironment, cervical lymph nodes, spleen, and thymus; and hematopoietic stem and progenitor cells in the bone marrow.

[Cell Death & Disease] Investigators revealed that HMGA1 and myosin heavy chain 9 (MYH9) were upregulated in gliomas and their expression correlated with WHO grade, and HMGA1 promoted the acquisition of malignant phenotypes and chemoresistance of glioma cells by regulating the expression of MYH9 through c-Jun-mediated transcription.

[Clinical Cancer Research] Researchers proved that anlotinib facilitated tumor vessel normalization at least partially through CD4+ T cells, reprogrammed the immunosuppressive tumor microenvironment (TME) into an immunostimulatory TME, significantly inhibited tumor growth and effectively prevented systemic immunosuppression.

[Translational Oncology] Researchers found that sensitivity toTemozolomide (TMZ) was suppressed by significantly increasing the major vault protein (MVP) expression in glioblastoma multiforme cells with TMZ resistance.

[Cell Death Discovery] Investigators found that pyrvinium pamoate (PP) and Temozolomide (TMZ) had synergistic effect on inhibiting the viability of glioblastoma multiforme (GBM) cells, and PP induced inhibition of MGMT and enhanced the TMZ chemosensitivity of GBM cells through down-regulating Wnt/β-catenin pathway.